SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel...
Hence then, the article about wuxi biologics and sinorda biomedicine enter strategic collaboration to accelerate development and manufacturing of innovative bispecific antibody was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody )
Also on site :
- Brandon Sanderson’s Literary Fantasy Universe ‘Cosmere’ Picked Up by Apple TV (Exclusive)
- LIVE: Benfica vs Real Madrid – UEFA Champions League
- Bad Bunny's Super Bowl Guest List Could Include Other Major Stars